PPP2R2A and prostate carcinoma: After the studies included in this analysis were initiated, data from the PROfound study demonstrated that no benefit of olaparib over control therapy was observed in patients with prostate cancer and PPP2R2A mutations and was not predictive of benefit from PARP inhibitor therapy [37].